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ABSTRACT
Triple negative breast cancer (TNBC) is a highly metastatic cancer among the 
breast cancer subgroups. A thorny issue for clinical therapy of TNBC is lack of an 
efficient targeted therapeutic strategy. We previously created a novel sesquiterpene 
lactone analog (named DETD-35) derived from plant deoxyelephantopin (DET) which 
exhibits potent effects against human TNBC MDA-MB-231 tumor growth in a xenograft 
mouse model. Here we studied the mechanisms of both DET and DETD-35 against 
MDA-MB-231 cells. DETD-35 (3-fold decreased in IC50) exhibited better anti-TNBC cell 
activity than DET as observed through induction of reactive oxygen species production 
(within 2 h treatment) and damage to the ER structures, resulting in ER-derived 
cytoplasmic vacuolation and ubiquitinated protein accumulation in the treated cells. 
Intriguingly, the effects of both compounds were blockaded by pretreatment with 
ROS scavengers, N-acetylcysteine and reduced glutathione, and protein synthesis 
inhibitor, cycloheximide. Further, knockdown of MEK upstream regulator RAF1 and 
autophagosomal marker LC3, and co-treatment with JNK or ERK1/2 inhibitor resulted 
in the most significant attenuation of DETD-35-induced morphological and molecular 
or biochemical changes in cancer cells, while the inhibitory effect of DET was not 
influenced by MAPK inhibitor treatment. Therefore, DETD-35 exerted both ER stress-
mediated paraptosis and apoptosis, which may explain its superior activity to DET 
against TNBC cells. Although the chemotherapeutic drug paclitaxel induced vacuole-
like structures in MDA-MB-231 cells, no paraptotic cell death features were detected. 
This study provides a strategy for combating TNBC through sesquiterpene lactone 
analogs by induction of oxidative and ER stresses that cause paraptosis-like cell death.
INTRODUCTION
Breast cancer is the most commonly diagnosed 
cancer in women, with 246,660 new cases diagnosed and 
40,450 deaths in the United States in 2016 [1]. Although 
various clinical therapeutic options including primary 
surgery, radiotherapy, pre- or postoperative adjuvant 
chemotherapy, and hormonal therapy are current common 
treatments for breast cancer that improve survival rates, 
anti-cancer drug resistance, and locally advanced and 
metastatic breast cancer still remain clinical challenges 
[2, 3]. Clinically, breast cancer is divided into several 
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different subgroups that are commonly classified based 
on the expression status of various receptors such as 
the estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2), 
among which triple negative (ER-/PR-/HER2-) breast 
cancer (TNBC) reveals highly metastatic features and 
poor prognosis. In addition, TNBC is accompanied by 
higher risk of early recurrence, and shorter disease-free 
and overall survival compared to all other breast tumor 
subgroups [4, 5].
For decades, plant-derived phytocompounds alone 
or in combinational chemotherapy have been used as 
strategies for cancer prevention in various allograft or 
xenograft animal models. One particular phytoagent that 
has attracted attention recently is deoxyelephantopin 
(DET), a major germacranolide sesquiterpene lactone 
isolated from the traditional medicinal herb Elephantopus 
scaber L. or other Elephantopus genus plants. In Chinese 
medicine, Elephantopus scaber is used for treating 
hepatitis, bronchitis, nephritis, arthralgia, or stomach 
disease symptoms [6, 7]. In our previous studies, we 
observed that DET is the active compound in the medicinal 
plant which was found to significantly suppress mammary 
tumor growth and lung metastasis of TS/A (ER+) mammary 
cancer cells in vivo and in vitro, and restrict cancer cell 
activity through regulating multiple molecular mechanisms, 
including formation of centrosomal aggregates, 
deregulation of the ubiquitin-proteasome system and NF-
κB activity, induction of ROS/JNK-mediated apoptosis 
and protein carbonylation, and restriction of cell motility 
by inhibiting m-calpain enzyme activity [8–10]. To further 
enhance and broaden the suppressive effects of DET 
against cancers, we created a spectrum of DET derivatives 
(DETDs) by semi-organic synthesis and determined the 
most active, which we named DETD-35 [11]. DETD-35 
exhibited more potent activity than parental DET, markedly 
repressing tumor growth and lung metastasis in MDA-
MB-231 tumor-bearing SCID mice; however, the detail 
molecular mechanisms underlying the activity of DET and 
DETD-35 were not elucidated.
Cytoplasmic vacuolation-related cell death, such as 
paraptosis or paraptosis-like cell death is a kind of non-
apoptotic and non-autophagic programmed cell death. This 
type of cell death has recently been proposed as a novel 
therapeutic strategy which may effectively inhibit the activity 
of drug-resistant cancer cells that have intrinsic or adaptive 
resistance to apoptosis, and thus reduce the therapeutic 
limitations of anti-cancer agents that are primarily dedicated 
to induction of pro-apoptotic cell death [12–14]. However, 
the molecular mechanisms underlying cytoplasmic 
vacuolation-related paraptosis are less understood than other 
types of programmed cell death, particularly in the area of 
natural products or chemotherapeutical drug-induced effects 
against cancer cells [15].
In this study, we uncovered the modes of action 
of both parental DET and its novel derivative DETD-
35 against MDA-MB-231 TNBC cells. We observed 
that DETD-35 significantly induced oxidative stress that 
subsequently facilitated ER dysfunction and paraptosis-
like cell death as shown by ER-associated massive 
cytoplasmic vacuole formation, and ER stress-mediated 
apoptosis or paraptosis in cancer cells. Part of the 
mechanism was also observed in DET treatment. This 
study is the first to show that sesquiterpene lactones can 
promote oxidative stress-induced cytoplasmic vacuolation 
death mechanisms to suppress TNBC cell activity.
RESULTS
DET and DETD-35 inhibited cell proliferation 
and growth and induced cytoplasmic vacuolation 
formation in MDA-MB-231 cells
The effect of DET and DETD-35 on human TNBC 
cell proliferation and phenotype were investigated. The 
cytotoxicity of DET, DETD-35, and paclitaxel (PTX), 
a chemotherapeutic drug for TNBC used as a reference, 
were examined at the indicated concentrations for 
24 h. DETD-35 was a more potent suppressor of MDA-
MB-231 cell viability than the parental compound DET 
with 50% inhibition concentrations (IC50) determined 
as 3.62 and 11.24 μM, respectively. PTX reduced cell 
viability by about 50% at around 1 μM. Both compounds 
had little effect (~20% inhibition) on proliferation of 
a normal human mammary epithelial cell line (MCF-
10A) at concentrations around their IC50 values against 
cancer cells; however, some cytotoxicity was detected 
when compound concentration was increased (Figure 
1A). Previously, we examined the in vivo effect of both 
compounds against MDA-MB-231 cell activity in an 
orthotopic tumor model using NOD/SCID mice [11]. We 
observed that treatment with DETD-35 (10 mg/kg/every 
three days, i.p.) or DET (20 mg/kg/every three days, i.p.) 
suppressed tumor size 40-44% compared to the tumor 
control group with vehicle treatment, and there was no 
significant difference in the body weight of test mice in 
any of the groups. In this study, the levels of proliferation 
marker Ki-67 were examined in tumor tissues and showed 
significant inhibition in DET- and DETD-35-treated 
groups compared to the tumor control group (P < 0.05) 
(Supplementary Figure 1). The in vitro and in vivo data 
demonstrate that DETD-35 has a more potent effect than 
the parental DET against triple negative breast cancer cell 
proliferation and growth.
Further, both DET and DETD-35 at 11 μM and 3 
μM, respectively, significantly induced the formation of 
massive cytoplasmic vacuoles in the perinuclear region 
of MDA-MB-231 cells treated for 24 h, as examined by 
light microscopy. PTX treatment (1 μM) also generated 
some vacuole-like structures near the nuclear region of 
MDA-MB-231 cells (Figure 1B). We further examined 
the detailed morphology of treated TNBC cells using 
transmission electron microscopy (TEM). As shown in 
Figure 1C, after treatment for 24 h, several empty vacuoles 
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Figure 1: Effects of DET and DETD-35 on MDA-MB-231 cells. (A) Chemical structure of paclitaxel (PTX), deoxyelephantopin 
(DET) and its derivative DETD-35; MDA-MB-231 and MCF-10A cells were treated with the indicated concentrations of DET, DETD-35, 
and PTX for 24 h, and then the cell viability was examined using MTT assay. (B) MDA-MB-231 cells were treated with vehicle (0.5% 
DMSO), DET (11 μM), DETD-35 (3 μM), and PTX (1 μM) for 24 h, and the morphological changes of cancer cells were examined by light 
microscopy (×400 magnification). (C) Transmission electron microscopy (TEM) imaging (×10,000 magnification) of untreated (vehicle) 
and treated (DET, 11 μM; DETD-35, 3 μM; PTX, 1 μM) MDA-MB-231 cells. The ER and mitochondria (mt) are indicated by black 
arrowheads and white arrowheads, respectively.
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had appeared in DET- and DETD-35-treated MDA-
MB-231 cells with the plasma membrane retained intact, 
but with a lack of detectable cytoplasmic materials. PTX 
treatment induced the appearance of multiple micronuclei 
within cells, and generated several vacuole-like structures 
containing rich and dense contents; different from the 
observations for DET or DETD-35 treatment (Figure 
1C). The multiple ribosomes embedded on the rough 
endoplasmic reticulum (RER) membrane, a feature of 
RER structures, were found in the vehicle and PTX-
treated TNBC cells, but were not seen after either DET or 
DETD-35 treatment. Meanwhile, both DET and DETD-35 
caused significant damage to the mitochondrial structures 
in the treated TNBC cells. A large population of swollen 
mitochondria was observed in DETD-35-treated cells and 
severe damage to mitochondria structural integrity was 
observed in DET-treated cells in comparison to vehicle-
treated cells. PTX treatment did not cause any apparent 
mitochondrial damage, except obvious multi-nuclei 
formation. Together, these results indicate that both DET 
and DETD-35 treatment induced the formation of massive 
cytoplasmic vacuoles and damaged the integrity of ER and 
mitochondrial structures in human TNBC cells; and the 
effect seen was obviously different from the PTX effect.
DETD-35 promotes non-autophagic cytoplasmic 
vacuolation death in TNBC cells
To further pinpoint the potential molecular 
mechanisms of DET- and DETD-35-induced cytoplasmic 
vacuolation in inhibition of TNBC cell activity, we first 
examined whether compound-stimulated cytoplasmic 
vacuolation is related to autophagic cell death. The 
accumulation of autophagic vacuoles has been reported 
to promote cancer cell death through deregulation of 
lysosomal membrane permeabilization [16]. In addition, 
the different stages of the autophagic process can be 
indicated using distinct autophagy marker proteins. We, 
therefore, used two different kinds of autophagy inhibitor, 
3-methyladenine (3-MA), an inhibitor that inhibits 
autophagy by blocking pre-autophagosome formation via 
the inhibition of class III phosphatidylinositol-3 kinase 
(PI3K), and bafilomycin A1 (BAF-A1), a vacuolar-type 
H+-ATPase (V-ATPase) inhibitor that inhibits fusion 
between autophagosomes and lysosomes. Further, we co-
treated the cancer cells with either DET or DETD-35 and 
measured cell viability, monitored cell morphology, and 
examined beclin-1 (an early stage marker of autophagy), 
LC3 (microtubule-associated protein 1 light chain 3, an 
autophagosomal marker) and p62 (a marker of autophagic 
flux at a later stage of autophagy) protein expressions in 
MDA-MB-231 cells.
As shown in Figure 2A, co-treatment with either 
3-MA or BAF-A1 slightly affected DET (-10%) or 
DETD-35 (±10%) cytotoxicity against MDA-MB-231 
cells, while no impact was observed in PTX-treated 
cells. Light microscopy showed that co-treatment with 
these autophagy inhibitors did not diminish the ability of 
DET and DETD-35 to induce cytoplasmic vacuolation 
in MDA-MB-231 cells (Figure 2B), suggesting that the 
cytoplasmic vacuolation-mediated cell death induced by 
both compounds in MDA-MB-231 cells may be through 
a non-autophagic type of cell death. Further, western 
blot analysis of the expression level of autophagy marker 
proteins in the control or treated cells revealed that, in 
the presence or absence of 3-MA or BAF-A1 inhibitor, 
DET-suppressed beclin-1 and p62 protein levels did not 
change, but DET-induced increased protein expression 
of LC3-II, an autophagic vesicle form associated 
marker, was slightly attenuated by co-treatment with 
3-MA (Figure 2C), while co-treatment with BAF-A1 
enhanced the protein level of DET-stimulated LC3-II. 
Neither autophagy inhibitor had an influence on DETD-
35-reduced beclin-1 expression, but 3-MA slightly 
decreased LC3-II accumulation, and BAF-A1 enhanced 
LC3-II and p62 accumulation in the DETD-35-treated 
cells (Figure 2C). On the other hand, cancer cells treated 
with PTX alone decreased the beclin-1 level which 
was not affected when cells were co-treated with PTX 
plus either inhibitor, in comparison with the control. 
Interestingly, PTX co-treated with BAF-A1 affected the 
expression level of LC3-II and p62 more significantly. 
Overall, the data reveal that treatment with either DET 
or DETD-35 induced an incomplete autophagic process 
in cancer cells.
To further confirm the role of autophagosomal 
LC3-II in DET- and DETD-35-induced cytoplasmic 
vacuolation, we knocked down LC3 expression in 
MDA-MB-231 cells using small hairpin RNA (shRNA) 
(Figure 2D). We observed partially increased viability of 
treated LC3-knockdown TNBC cells along with some 
degree of reduction of cytoplasmic vacuoles in both DET 
(13%) and DETD-35 (18%) treatment due to reduced 
accumulation of autophagosomal LC3-II. No changes 
were observed in the PTX-treated cells with or without 
knockdown of LC3-II (Figure 2D). Next, we examined 
whether the autophagosome accumulation stimulated by 
either compound observed in the cell line also appeared 
in MDA-MB-231 tumor specimens collected from the 
xenograft mice with either DET or DETD-35 treatment 
from our recent animal study [11]. Immunohistochemical 
(IHC) analysis showed that the expression level of 
autophagosomal marker LC3 significantly increased in 
DET- and DETD-35-treated TNBC tumor specimens 
(Figure 2E), which perfectly matched the markedly 
induced autophagosomal protein accumulation in MDA-
MB-231 cells in vitro. Taking both the in vitro and in 
vivo data together, we conclude that DET derivatives, 
especially DETD-35 induced non-autophagic cytoplasmic 
vacuolation-mediated cell death in MDA-MB-231 cells, 
which was at least in part through significant induction of 
autophagosome (LC3-II) accumulation.
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Figure 2: DET and DETD-35 induce nonautophagic cytoplasmic vacuolation death in TNBC cells. (A) Autophagy 
inhibitors, 3-methyladenine (3-MA) or bafilomycin A1 (BAF-A1), were co-treated with either vehicle (0.5% DMSO) or compounds (DET, 
11 μM; DETD-35, 3 μM; PTX, 1 μM) for 24 h. The viability of treated MDA-MB-231 cells was determined using MTT assay. Different 
letters represent significant differences (one-way ANOVA, P < 0.05). (B) MDA-MB-231 cells were treated with vehicle and compounds 
alone, or compounds with autophagy inhibitors (2.5 mM 3-MA and 10 nM BAF-A1) for 24 h, and then the morphological changes in the 
treated cells were observed using light microscopy (×400 magnification). (C) Whole cell protein extracts were prepared after the various 
treatments described in (B), and the expression levels of three different autophagy marker proteins, beclin-1, LC3-II, and p62, were 
further examined by western blotting. Quantification of the corresponding protein bands was performed using Image Studio Lite software. 
β-actin was used as a loading control. (D) LC3 gene expression was knocked down using shRNA (shRNA LC3), and shLacZ was used 
as a control shRNA. The shRNA-transfected TNBC cells were treated with vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 μM), and 
PTX (1 μM) for 24 h, and then subjected to MTT assay and light microscopy to check the cell viability and morphological changes in 
treated TNBC cells. The transfected TNBC cell lysates were immunoblotted with LC3 antibodies. β-actin was used as a loading control. 
(E) Representative immunohistochemical images of orthotopic MDA-MB-231 tumor sections from tumor control (without treatment) 
and DET or DETD-35 treated NOD/SCID mice. The positive LC3 staining was visualized as a brownish color, and nuclei were stained 
by hematoxylin and shown in blue color. Scale bar represents 50 μm. Data are mean ± SEM, n = 3. Different letters represent significant 
differences (one-way ANOVA, P < 0.05).
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DET- and DETD-35-caused cytoplasmic 
vacuolation death is associated with endoplasmic 
reticulum (ER) stress and ubiquitinated protein 
accumulation
According to the light microscopy and TEM 
analysis results, DET and DETD-35 treatment was able to 
disrupt the ER structure in MDA-MB-231 cells, possibly 
as a result of ER stress. Previously, ER stress and protein 
ubiquitination have been associated with cytoplasmic 
vacuolation-mediated cell death [15]. We thus further 
examined whether both DET- and DETD-35-induced 
cytoplasmic vacuolation accompanies accumulation 
of ubiquitinated proteins and ER stress-related protein 
increase in MDA-MB-231 cells. The western blotting 
result revealed that both compounds markedly promoted 
the accumulation of ubiquitinated proteins in treated 
MDA-MB-231 cells relative to the control cells. DETD-
35 treatment stimulated a relatively greater degree of 
ubiquitinated protein accumulation at short treatment 
durations (4 and 8 h); whereas, DET treatment induced 
more at 12 and 24 h (Figure 3A). We next checked 
for ER damage and/or misfolded or unfolded protein 
accumulation that could trigger ER stress and the related 
signaling pathways such as unfolded protein response 
(UPR) signaling. We observed that DET and DETD-35 
significantly up-regulated ER stress-related proteins, 
including the phosphorylated form of eukaryotic initiation 
factor-2α (eIF2α), a well-known substrate of protein kinase 
RNA (PKR)-like ER kinase (PERK), at 4-8 h treatment 
and inositol-requiring protein-1α (IRE1α), one of the 
major UPR signaling molecules (Figure 3B). Meanwhile, 
both DET and DETD-35 treatments were also able to 
promote the expression of Bim, a pro-apoptotic BH3-
only group of Bcl-2 related proteins that plays an essential 
role in ER stress-mediated apoptosis. Interestingly, the 
protein level of protein disulfide isomerase (PDI), an 
ER-associated enzyme, was not altered by treatment with 
either compound. Next, we examined the expression 
of programmed cell death hallmarks, poly ADP-ribose 
polymerase (PARP) and caspase-7. We observed that, 
within 24 h, DETD-35 treatment caused more apoptotic 
cell death than DET treatment in MDA-MB-231 cells. 
Besides inducing ER stress, overloading of misfolded 
proteins in the ER lumen of cells may also cause ER 
dilation which is positively associated with cytoplasmic 
vacuolation. Therefore, immunofluorescence staining 
of the ER-membrane bound protein, calnexin, was 
conducted in control and treated cancer cells. As shown in 
the confocal fluorescence images in Figure 3C, there was 
positive and evenly distributed calnexin staining (green) 
in the cytoplasm of vehicle control cells. Strikingly, in 
DET- and DETD-35-treated cells, the positive calnexin 
staining took place at the membrane surrounding the 
enlarged vacuoles in the cytosol, suggesting that both 
DET- and DETD-35-induced cytoplasmic vacuoles 
originated from the ER in MDA-MB-231 cells. Such ER 
dilation and derived vacuoles were not observed in PTX-
treated cells. Together, these findings indicate that both 
DET- and DETD-35-induced cytoplasmic vacuolation and 
cell death were associated with de-regulation of ubiquitin 
proteasome proteolysis and ER function and the associated 
stress signaling.
DET- and DETD-35-induced cytoplasmic 
vacuolation require protein synthesis
As we observed ER dilation in MDA-MB-231 cells 
treated with DET derivatives, it was worth investigating 
whether the protein synthesis machinery is associated 
with the cytoplasmic vacuolation-related cell death 
caused by DET and DETD-35. Protein synthesis inhibitor, 
cycloheximide (CHX) was used to pretreat MDA-MB-231 
cells followed with or without compound treatment. Cell 
viability, cytoplasmic vacuolation and ubiquitinated 
protein levels in the cancer cells were examined. 
Pretreatment with CHX (10 and 50 μg/mL) in vehicle 
control cells showed some inhibition (< 24%) of MDA-
MB-231 cell proliferation compared to the vehicle control 
in the absence of CHX (Figure 4A). CHX pretreatment 
restored DET-, DETD-35-, and PTX-inhibited cell 
viability by around 14-17% compared to compound or 
PTX treatment alone, while CHX at 10 μg/mL prevented 
the formation of vacuole structures most significantly 
in DETD-35-treated cells. A more potent effect was 
detected for 50 μg/mL CHX pretreatment in DET-treated 
cells (Figure 4A). Furthermore, pretreatment with a low 
concentration (10 μg/mL) of CHX markedly reduced 
DETD-35-induced ubiquitinated protein accumulation 
and the expression levels of Bim, autophagosomal marker 
LC3-II and cleaved forms of PARP and caspase-7 in 
TNBC cells compared to DET or PTX treatment (Figure 
4B and 4C). These results demonstrated that treatment 
with protein synthesis inhibitor CHX can partially 
neutralize the ability of DET, and DETD-35 to repress 
TNBC cell activity and programmed cell death.
Role of MAP kinases in DET- and DETD-35-
induced cytoplasmic vacuolation death in TNCB 
cells
Activation of mitogen-activated protein kinases 
(MAPKs) has often been described to be involved in 
paraptosis/paraptosis-like cell death and/or cytoplasmic 
vacuolation-mediated cell death in cancer cells [12, 17]. 
Therefore, we examined the activation status of MAPKs 
during DET and DETD-35 treatment at 4 to 24 h, and 
found that both compounds can significantly enhance 
both phosphorylation levels of extracellular signal-
regulated kinase (ERK) and c-Jun N-terminal kinase 
(JNK). In comparison, DET had a more significant effect 
on phospho-ERK at shorter treatment times (4-8 h) while 
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Figure 3: DET and DETD-35 significantly induce ubiquitinated protein accumulation, and ER stress and dilation in 
MDA-MB-231 cells. (A) Immunoblotting of ubiquitinated proteins in MDA-MB-231 cells treated with vehicle (0.5% DMSO), DET (11 
μM), or DETD-35 (3 μM) for 4, 8, 12, and 24 h. The expression level of β-actin was used as a loading control. (B) The protein level of ER 
stress-related proteins, p-eIF2α, IRE1α, PDI, and Bim, and apoptosis-related proteins, the cleaved form of PARP and caspase-7, in vehicle 
or compound treated cells were determined by western blotting. GAPDH was used as a loading control. (C) Immunofluorescence analysis 
of MDA-MB-231 cells treated with vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 μM), or PTX (1 μM) for 24 h. The treated cells 
were fixed using 100% ice-cold methanol, and stained with calnexin, an ER-membrane bound protein (green), and DAPI (blue) to visualize 
ER structures and nuclei. White arrows indicate DET- and DETD-35-induced cytoplasmic vacuoles.
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DETD-35 promoted phospho-JNK expression time-
dependently from 4 to 24 h treatment; moreover, DETD-
35 also increased phospho-p38 level; this increase was 
not observed in DET-treated cells (Figure 5A). Based 
on the western blot data, we decided to employ various 
MAP kinase inhibitors, i.e., SB203580 (p38 MAP kinase 
inhibitor), selumetinib (ERK1/2 or MEK1 inhibitor) and 
SP600125 (JNK inhibitor), to investigate whether specific 
MAP kinase activity is associated with the compound 
effects on anti-TNBC cell proliferation and/or the 
induction of cancer cell cytoplasmic vacuolation and cell 
death. First, we observed that the three MAPK inhibitors 
did not affect the DET cytotoxicity against MDA-MB-231 
cells, but ERK1/2 inhibitor and JNK inhibitor co-treatment 
attenuated approximately 23% and 14%, respectively of 
DETD-35 cytotoxic activity, interestingly JNK inhibitor 
reversed ~30% of PTX cytotoxicity (Figure 5B). On the 
other hand, co-treatment with either ERK1/2 or JNK 
inhibitor reduced DETD-35-induced cytoplasmic vacuole 
formation in TNBC cells (Figure 5C). This result is in 
good agreement with the reversal effect of the inhibitors 
on the compound cytotoxicity (Figure 5B). Furthermore, 
a reversal effect of JNK inhibitor on PTX cytotoxicity and 
PTX-induced vacuole-like structures in MDA-MB-231 
cells was also observed (Figure 5B and 5C). Although we 
observed the overphosphorylation of ERK protein with 
DET treatment, we could not detect the ERK1/2 inhibitor 
effect on DET cytotoxicity and DET-induced cytoplasmic 
vacuolation. Meanwhile, the p38 MAP kinase inhibitor 
did not significantly affect the cytotoxicity of DET, 
Figure 4: Pretreatment of protein synthesis inhibitor prevents DET- and DETD-35-triggered cytoplasmic vacuolation 
death in TNBC cells. (A) MDA-MB-231 cells were pretreated with protein synthesis inhibitor, cycloheximide (CHX 10 or 50 μg/mL), 
for 1 h, and subsequently treated with vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 μM), and PTX (1 μM) for 24 h. Cell viability was 
determined using MTT assay. Different letters represent significant differences (one-way ANOVA, P < 0.05). Phase-contrast microscopic 
images of the compound and/or CHX effect on vacuole formation in TNBC cells. Immunoblotting of ubiquitinated protein profile and 
levels (B) and the levels of apoptosis-related proteins (cleaved PARP and cleaved caspase-7), ER stress-associated protein (Bim), and 
autophagosomal marker protein LC3-II (C) in treated TNBC cells. β-actin was used as a loading control.
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DETD-35, and PTX and their induced vacuole formation 
and cell death in the treated TNBC cells. Therefore, we 
employed the ERK1/2 and JNK inhibitor, selumetinib 
and SP600125, respectively, to further confirm whether 
both MAPK inhibitors could abolish both compound-
stimulated ERK and JNK activation. Indeed, western blot 
analysis revealed that the inhibition of phospho-MAPKs 
with selumetinib and SP600125 blocked DET/DETD-35-
stimulated overexpression of phospho-ERK and phospho-
JNK in MDA-MB-231 cells; meanwhile, both inhibitors 
significantly decreased DETD-35-induced expression of 
JNK substrate p21WAF1/Cip1 and only JNK inhibitor affected 
PTX-induced p21WAF1/Cip1 level, whereas no effect was 
observed in DET treatment. Interestingly, LC3-II protein 
level was only attenuated by ERK1/2 inhibitor in DETD-
35-treated cells (Figure 5D), suggesting the overexpression 
of phospho-ERK during DETD-35 treatment may partially 
participate in the mechanism of DETD-35-induced 
autophagosome accumulation in treated cells. These data 
suggest that ERK and JNK are involved in the DETD-35- 
and DET-mediated cytoplasmic vacuolation in TNBC cells 
to a different degree.
We further knocked down v-raf-1 murine leukemia 
viral oncogene homolog 1 (RAF1), an upstream regulator 
gene of the MEK signaling pathway, using shRNA to 
see whether the compound cytotoxicity or induction of 
vacuole formation in cancer cell cytoplasm was affected. 
The results, shown in Figure 5E, reveal an attenuation 
of DET (12%), DETD-35 (26%), and PTX (22%) 
cytotoxicity by knockdown of RAF1 in the cancer cells. 
A more significant reversion of the vacuoles formed in the 
cytoplasm was seen with DETD-35 treatment than with 
DET or PTX treatment (Figure 5E). The data indicate 
that RAF1-mediated MEK signaling networks are likely 
involved in DETD-35-induced cytoplasmic vacuolation 
death in human TNCB cells.
DET- or DETD-35-induced ROS mediates 
cytoplasmic vacuolation-associated cell death
We observed previously that DET or DETD-35 
treatment could induce the production of reactive oxygen 
species (ROS) in mouse TS/A mammary cancer cells 
[9] or human BRAF mutant A375 melanoma cells [18]. 
The cytotoxic effect of both compounds was attributed to 
this ROS production. We thus further evaluated whether 
DET and DETD-35 can increase ROS level in the human 
TNBC MDA-MB-231 cells and cause the activation of 
ER stress-related pathways and cytoplasmic vacuolation-
associated cell death in the cancer cells. As shown in 
Figure 6A, treatment with DET or DETD-35 significantly 
triggered ROS production in MDA-MB-231 cells. ROS 
production was also found in PTX-treated MDA-MB-231 
cells, but at a far lower level than with DET or DETD-
35 treatment. Next, the cancer cells were pretreated with 
various ROS scavengers such as N-acetylcysteine (NAC), 
thiol antioxidant (reduced glutathione, GSH), manganese 
superoxide dismutase (SOD) mimetic [Mn(III) tetrakis 
(4-benzoic acid) porphyrin chloride, MnTBAP], and H2O2 
scavenger (catalase-polyethylene glycol) before DET, 
DETD-35, or PTX treatment. NAC and thiol antioxidant 
GSH pretreatment almost completely abrogated the DET 
and DETD-35 cytotoxicity and the cytoplasmic vacuoles 
they induced; whereas, pretreatment with MnTBAP and 
H2O2 scavenger catalase did not show any effect (Figure 
6B and 6C). Of note, pretreatment with the four different 
ROS scavengers did not reverse the formation of vacuole-
like structures or proliferation activity in PTX-treated 
TNBC cells. On the other hand, the accumulation of 
ubiquitinated proteins, ER stress-related proteins (IRE1α 
and Bim), autophagosomal marker LC3-II, and phospho-
JNK in the cells under DET and DETD-35 treatment were 
also significantly counteracted by pretreatment with NAC 
or GSH (Figure 6D), indicating that DET and DETD-35 
treatment can facilitate a specific type of ROS production, 
apart from MnSOD-produced ROS and H2O2. This ROS 
production is undoubtedly a crucial upstream initiator 
of the suppressive effects of DET and DETD-35 against 
TNBC cell activity. Collectively, these results show that 
cytoplasmic vacuolation-mediated cell death upon DET 
and DETD-35 treatment in TNBC cells is partly through 
the ROS-mediated ER stress signaling pathways.
DISCUSSION
Anti-cancer drug-induced apoptosis is one of the 
mechanisms most commonly utilized in cancer therapy; 
however, cancer cells may develop different adaptive or 
innate mechanisms, such as modification and mutation of 
drug targets, alteration of drug metabolism and transport, 
enhancement of DNA repair, and dyregulation of apoptotic 
proteins, to promote the formation of apoptosis-resistant 
cancer cells resulting in severely limited anti-cancer 
drug efficacy [19]. Recently, targeting several forms 
of non-apoptotic programmed cell death (PCD), such 
as autophagy, paraptosis, necroptosis, pyroptosis, and 
cytoplasmic vacuolation-mediated cell death have been 
demonstrated to be effective [12, 20, 21] and have been 
considered as new strategies for preventing or combating 
malignant cancer.
Various natural products, such as curcumin and 
paclitaxel, have been reported to function as anti-cancer 
agents by inducing paraptotic PCD in cancer cells 
through inducing extensive cytoplasmic vacuolation 
beginning from progressive organelle ER and/or 
mitochondria dilation [12]. In this study, we observed 
for the first time that plant-derived sesquiterpene lactone 
DET and its derivative could significantly induce ER 
dilation and cytoplasmic vacuole formation in the 
triple negative breast cancer cell line MDA-MB-231. 
Regulation of autophagosomal marker LC3 has been 
found to be involved in cytoplasmic vacuolation-
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Figure 5: Effects of MAPK inhibitors on DET, DETD-35, and PTX-induced cytoplasmic vacuole formation in TNBC 
cells. (A) MDA-MB-231 cells were lysed after treatment with vehicle (0.5% DMSO), DET (11 μM), and DETD-35 (3 μM) for the indicated 
time periods (4, 8, 12, and 24 h), and then subjected to western blotting to determine the expression levels of original and phosphorylated 
forms of p38, ERK, and JNK. β-actin was used as a loading control. (B) The indicated concentrations of MAPK inhibitors, SB203580 
for p38; selumetinib for ERK1/2; SP600125 for JNK, were co-treated with either vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 
μM), or PTX (1 μM) in MDA-MB-231 cells for 24 h. Cell viability was assessed using MTT assay. Different letters represent significant 
differences (one-way ANOVA, P < 0.05). (C) Phase-contrast microscope images show the influence of MAPK inhibitor (SB203580, 5 μM; 
selumetinib, 0.04 μM; SP600125, 20 μM) co-treatment with compound on vacuole formation. (D) Immunoblotting of ERK, p-ERK, JNK, 
p-JNK, JNK substrate p21WAF1/Cip1, and autophagosomal marker protein LC3-II in TNBC cells treated with vehicle and compound alone, 
or compound plus either selumetinib (0.04 μM) or SP600125 (20 μM) for 24 h. β-actin was used as a loading control. (E) Knockdown of 
RAF1 gene expression using shRNA (shRNA RAF1), and shLacZ was used as a control shRNA in the experiment. The shRNA-transfected 
TNBC cells were treated with vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 μM), and PTX (1 μM) for 24 h, and then subjected to 
MTT assay and light microscopy to evaluate the cell viability and morphological changes in treated TNBC cells. Transfected TNBC cell 
lysates were immunoblotted to validate the knockdown efficiency of shRNA RAF1 in vehicle or compound-treated cells. GAPDH was 
used as a loading control.
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Figure 6: Pretreatment with either NAC or GSH prevents DET and DETD-35 induced ROS production and cytoplasmic 
vacuolation-mediated cell death. (A) MDA-MB-231 cells were treated with vehicle (0.5% DMSO), DET (11 μM), DETD-35 (3 
μM), and PTX (1 μM) for 1 h. The detection of ROS production in the treated cells is described in the Materials and Methods section. 
(B) MDA-MB-231 cells were treated with the indicated concentrations of ROS scavengers, N-acetylcysteine (NAC), reduced glutathione 
(GSH), Mn(III)tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP), and catalase-polyethylene glycol (catalase-PEG) for 1 h, and 
then treated with the vehicle and compounds for 24 h. Cell viability was assessed using MTT assay. Different letters represent significant 
differences (one-way ANOVA, P < 0.05). (C) Phase-contrast microscopic images show the influence of ROS scavenger (NAC, 5 mM; 
GSH, 5 mM; MnTBAP, 50 μM; catalase, 1000 U/mL) pre-treatment alongside compound treatment on cytoplasmic vacuole formation. (D) 
Immunoblotting of ubiquitinated proteins, ER stress-associated proteins (phospho-eIF2α, IRE1α, and Bim), LC3-II, JNK, and p-JNK in 
the TNBC cells pre-treated with NAC (5 mM) and GSH (5 mM) for 1 h, and then treated with vehicle or compounds for 24 h. β-actin was 
used as a loading control.
associated death in cancer cells [13, 22]. Our data 
show that DET or DETD-35 stimulated considerable 
accumulation of LC3-II protein in MDA-MB-231 
cells as well as in the MDA-MB-231 tumor specimens 
collected from xenograft mice (Figure 2). Further, 
knockdown of LC3 expression in MDA-MB-231 cells 
with LC3 shRNA concurrently reduced the cytotoxicity 
and cytoplasmic vacuole formation caused by DET 
or DETD-35 in TNBC cells. Meanwhile, autophagy 
inhibitor BAF-A1 co-treatment also increased the anti-
proliferative effect of both compounds. These results 
indicate that autophagosome accumulation-induced cell 
death plays a role in the DET/DETD-35 effect against 
triple negative breast cancer cells.
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Autophagy is an evolutionarily conserved process 
in eukaryotes which responds to varied environmental 
stimuli such as oxidative stress, ER stress, hypoxia, and 
xenobiotic treatment. It participates in various basic 
cellular biological processes and pathologies, such as 
aging, differentiation, immunity, tumorigenesis, and 
cell death [23]. A complete autophagic process is made 
up of a series of sequential stages, including initiation 
of phagophore formation, autophagosome elongation 
and formation, and fusion of autophagosomes with 
lysosomes to form autophagolysosomes [24]. It was 
reported previously that knockdown of beclin-1, a 
protein representing the early stage of autophagy, using 
short interfering RNA (siRNA) can enhance ER stress-
mediated paraptosis by potentiating the expression of 
ER stress markers CHOP and Bip in germacrane-type 
sesquiterpenoid 8-p-hdroxybenzoyl tovarol-treated 
HeLa cells [25]. In this study, both promoting LC3-II 
protein expression for autophagosome formation, and 
de-regulating the beclin-1 protein by the germacranolide 
sesquiterpene lactone DET and its derivative in TNBC 
cells are likely correlated to ER stress-mediated paraptosis 
induced by both compounds (Figure 3).
p62, a marker of autophagic flux, was significantly 
decreased in DET-treated cells. Besides acting as an 
autophagic adaptor, p62 has also been demonstrated to be 
a multifunctional signaling adaptor of activation of NF-
κB-mediated inflammatory responses, NRF2-activated 
antioxidant defense, and mTORC1-dependent nutrient 
sensing [26]. Our previous study illustrated the novel 
anti-inflammatory activity of DET by deregulating NF-
κB activity through competing for the hydrogen bonding 
of the cis-acting DNA element to its p65 subunit [27] that 
might also be referred to as the deregulation of p62 in 
TNBC cells. 3-MA can prevent the formation of the pre-
autophagosomal structure at the early stage of autophagy, 
and BAF-A1 can disrupt the autophagosomal-lysosomal 
fusion at the late stage of autophagy. In this study, we 
observed that co-treatment with 3-MA can indeed attenuate 
the autophagosomal LC3-II expression induced by both 
compounds. On the other hand, inhibitor BAF-A1 acting at 
the later stage after autophagosome formation could increase 
the accumulation of autophagosomal LC3-II protein in 
compound-treated cells, but had no effect on the expression 
of beclin-1 and p62 in DET-treated TNBC cells, and p62 
was increased in DETD-35 treated cells. These results 
demonstrate that both compounds augment autophagosome 
accumulation to potentiate an incomplete autophagy event 
in TNBC cells resulting in non-autophagic, cytoplasmic 
vacuolation-mediated cell death.
Cytoplasmic vacuolation-mediated cell death, 
paraptosis, or paraptosis-like cell death by drug or natural 
product treatments, are often accompanied by ER stress 
and ubiquitinated protein accumulation, which have a 
cooperative reciprocal effect in repressing cancer cell 
activity [12, 15]. According to the light microscopy data 
and TEM analysis carried out in this study, both DET and 
DETD-35 treatment not only resulted in morphological 
changes by inducing cancer cell swelling but also 
damaged the integrity of the ER causing accumulation of 
ubiquitinated proteins and the upregulated the expression 
of ER stress-related proteins in treated cells. These 
data suggest DET/DETD-35 disrupted the ubiquitin-
proteasome system thus facilitating ER stress and caused 
accumulation of unfolded and misfolded proteins within 
the ER lumen that may result in ER stress-associated 
apoptotic or non-apoptotic programmed cell death in 
MDA-MB-231 cells. The extensive cytoplasmic vacuole 
formation, similar to that characteristic of paraptotic PCD, 
triggered by both compounds originated from the dilated 
ER structures. Protein synthesis inhibitor, cycloheximide 
(CHX) is known to play a role in preventing the dilation 
of cellular organelles, like the ER and/or mitochondria. 
Dilation of organelles is regarded as one of morphological 
features of paraptosis/paraptosis-like cell death and 
cytoplasmic vacuolation-mediated cell death [12, 28]. We 
observed that CHX markedly diminished both DET- and 
DETD-35-induced cytoplasmic vacuolation, ubiquitinated 
protein accumulation, and autophagosomal LC3-II and 
cell-death marker expression, phenomena that perfectly 
match the biochemical and morphological characteristics 
of paraptosis-like cell death [12].
Recently, we have demonstrated that DET- and/
or DETD-35-induced reactive oxygen species (ROS) 
production in mouse mammary cancer cells TS/A, or human 
BRAF mutant A375 melanoma cells [9, 18] resulting in 
cancer cell apoptosis. Therefore, we attempted to explore 
whether DET-/DETD-35-induced oxidative stress can 
confer paraptosis PCD in TNBC cells. Our data showed 
that DET, DETD-35, and PTX significantly promoted the 
generation of ROS, which could be reversed by pretreatment 
with antioxidant NAC or thiol antioxidant GSH, suggesting 
that the oxidative stress triggered by both compounds may 
be through covalent modification of sulfhydryl groups of 
cellular proteins, subsequently leading to the disruption of 
intracellular redox homeostasis; however, the role of thiol 
redox homeostasis in DET- and DETD-35-treated TNBC 
cells is still unclear and may warrant future investigation. 
Further, NAC and GSH can completely reverse DET- and 
DETD-35-induced cytotoxicity, cytoplasmic vacuolation, 
and the expression of related protein markers involved in 
ER stress or autophagosome accumulation. Interestingly, 
NAC or GSH pretreatment also completely abrogated the 
up-regulated expression of phosphorylated form of JNK 
in TNBC cells treated with either compound, but DET co-
treated with JNK inhibitor SP600125 had little or no effect 
on the DET cytotoxicity. In addition, DET up-regulated 
JNK substrate p21WAF1/Cip1. Previously we observed that co-
treatment of DET with JNK inhibitor SP600125 notably 
reduced DET induced p21WAF1/Cip1 and cleaved forms of 
PARP and caspase-3 in TS/A cells [8], indicating that DET 
acts differentially on the JNK activation and JNK-mediated 
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signaling in different breast cancer cell types. On the 
other hand, insulin-like growth factor I receptor (IGFIR)-
induced paraptosis was reported to be positively associated 
with the activation of MEK-2 and JNK [17]. Interestingly, 
co-treatment with JNK inhibitor SP600125 obviously 
attenuated the cytotoxic effect of DETD-35 and PTX in 
TNBC cells and its associated vacuole structure formation 
and p21WAF1/Cip1 expression. Moreover, similar inhibitory 
bioactivity was seen when DETD-35 was used together 
with ERK1/2 inhibitor selumetinib or with knockdown 
of tumor suppressor gene RAF1, a serine/threonine-
protein kinase, which not only diminished the cytoplasmic 
vacuole formation but subsequently restored the viability 
of treated TNBC cells. Furthermore, ERK1/2 inhibitor co-
treatment obviously reduced the up-regulated expression 
of autophagosomal marker LC3-II, demonstrating that the 
activation of MAPKs and the related signaling networks 
may be one of regulators that mediate DETD-35-stimulated 
paraptosis-like cell death. It is not clear at this stage how 
RAF1 and its related signaling pathways are involved in the 
DET/DETD-35 effect against TNBC cells.
PTX, the front-line chemotherapeutic drug for breast 
cancers, was used as a reference drug in this study. PTX 
caused vacuole-like particles or structures to occupy the 
nuclear space of MDA-MB-231 cells, an effect that could 
be reversed by CHX pre-treatment. In addition, no ER-
dilation was detected in PTX-treated cells. Moreover, 
only a slight decrease in beclin-1 protein expression and 
no effect on the LC3-II and p62 proteins was observed 
with PTX treatment. In addition, neither the autophagic 
inhibitors nor ERK/MEK-1 affected the cytotoxicity 
of PTX in treated TNBC cells, while JNK inhibitor and 
CHX were able to reverse the cell viability. These findings 
suggest the molecular mechanism of PTX on TNBC 
cells is quite different from that of the DET derivatives. 
However, it has been reported that high concentrations of 
PTX (such as 70 μM) could induce paraptosis-like cell 
death by inducing cytoplasmic vacuolization derived from 
ER in ASTC-a-1 lung cancer cells [29] or in A549 tumor-
xenograft mice in vivo [30]. It is worth mentioning, that 
we observed in our previous study that DET could induce 
ER stress and evoke ubiquitinated protein accumulation 
in TS/A ER(+) mammary cancer cells, but there was no 
ER dilation, cytoplasmic vacuoles formed, or typical 
paraptotic programmed cell death detected in the treated 
cancer cells. Instead, typical and significant ER stress-
mediated apoptosis and signaling cascades were elicited 
[8–10]. It is very interesting that in the same way that 
different actions of PTX were found in lung cancer cells 
[29, 30] and the TNBC cells observed in this study; the 
same DET compound induced common apoptosis in both 
ER(+) TS/A cells and triple negative MDA-MB-231 
cells, but only triggered distinct cytoplasmic vacuolation-
associated cell death in TNBC cells. A summary of the 
proposed mechanisms of action of DET and DETD-35 
against MDA-MB-231 cells is shown in Figure 7. This 
Figure 7: A summary of the proposed mechanisms of action of DET and DETD-35 against TNBC cells by induction of 
oxidative stress-mediated paraptosis-like cell death.
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study provides a new perspective on oxidative stress-
induced cytoplasmic vacuolation or paraptosis-mediated 
programmed cell death by a sesquiterpene lactone 
derivative that may constitute a promising therapeutic 
strategy for the treatment of apoptosis-resistant cancer or 
not-targetable triple negative breast cancer.
MATERIALS AND METHODS
Chemicals and antibodies
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), dimethyl sulfoxide (DMSO), paclitaxel 
(PTX), bafilomycin A1 (BAF-A1), N-acetyl-L-cysteine 
(NAC), cycloheximide (CHX), catalase-polyethylene glycol 
(PEG), 4,6-diamidino-2-phenylindole (DAPI), and reduced 
glutathione (GSH) were purchased from Sigma-Aldrich. 
3-Methyladenine (3-MA) and Mn(III) tetrakis (4-benzoic 
acid) porphyrin chloride (MnTBAP) were purchased from 
Merck Millipore. ERK/MEK1 inhibitor (selumetinib) was 
purchased from Selleck Chemicals. DMEM, FBS, and the 
antibiotics mixture (penicillin-streptomycin) were purchased 
from Invitrogen. Primary antibodies against β-actin 
(Chemicon, Millipore), p62 (BD Biosciences), LC3A/B 
and Ki-67 (Abcam), LC3B (Arigo Biolaboratories.), Raf1 
(GeneTex), PDI, caspase-7, Bim, phospho-eIF2α, phospho-
ERK1/2, phospho-SAPK/JNK, phospho-p38 MAPK (Cell 
Signaling Technology) were used. All other antibodies were 
obtained from Santa Cruz Biotechnology.
Preparation of DET and its derivative DETD-35
The isolation and identification of DET from the 
Elephantopus scaber L. plant followed the protocol 
described by Huang et al. [8]. The synthesis of DETD-35 
followed the method reported by Nakagawa-Goto et al. [11].
Cell culture
Normal human mammary epithelial cells, MCF-
10A, and triple negative human breast cancer cells, 
MDA-MB-231, were grown in the manufacturers’ 
suggested medium supplemented with 10% fetal bovine 
serum (FBS), 100 units/mL penicillin, and 1 mM sodium 
pyruvate (Gibco), and incubated in a humidified 5% CO2 
incubator at 37°C.
Cell viability assay
Normal and breast cancer cells (5 × 103 cells/well) 
were seeded in 96-well culture plates and incubated 
overnight to allow cell adhesion. The cells were treated 
with vehicle (0.5% DMSO), DET, DETD-35 or PTX at 
the indicated concentrations for 24 h. Cell growth was 
determined by using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT)-based colorimetric 
assay as previously reported [31].
Animals
Female NOD/SCID mice (NOD.CB17-Prkdcscid/
IcrCrlBltw) were supplied by the Laboratory Animal 
Core Facility (BioLASCO, Taiwan) and given a standard 
laboratory diet and distilled H2O ad libitum and kept on 
a 12 h light/dark cycle at 22 ± 2°C. All experimental 
protocols (No: 11-02-137) were approved by the 
Institutional Animal Care and Utilization Committee 
(IACUC), Academia Sinica, Taiwan, R.O.C.
Inhibition of triple negative tumor growth in 
NOD/SCID mice
Triple negative mammary tumor response to DET 
and DETD-35 was studied using MDA-MB-231 cancer 
cells bearing NOD/SCID mice (6 weeks old). The 
mammary fat pad regions of mice were injected with 5 × 
106 MDA-MB-231 cells in 100 μL (9.1 mg/mL) Matrigel 
(Basement Membrane Matrix, Phenol Red-free) on day 0. 
Tumors were allowed to grow in the mice for 7 days, and 
then the animals were randomly assigned to three groups 
(n = 5 per group): sham, tumor control (vehicle treated), 
20 mg/kg DET, and 10 mg/kg DETD-35 treatment 
group. DET and DETD-35 were intraperitoneally (i.p.) 
injected every three days. Mouse body weights were 
recorded every three days. The test mice were sacrificed 
by cervical dislocation at day 69, and the tumors were 
collected and measured for the volume (V) using calipers 
and calculated by the formula V = (L × W2)/2, where L 
is the length and W is the width of tumor. H&E staining 
and immunohistochemistry analysis of tumor tissues was 
carried out according to the method described by Feng et 
al. [18]. The sections were stained with rabbit antibody 
against Ki-67 or LC3A/B (Abcam) for IHC analysis. 
The expression level of immunostaining targeted protein 
was examined by use of AxioVision software (Carl Zeiss 
MicroImaging).
Western blot analysis
Cells were harvested and washed with ice-cold PBS, 
and subsequently lysed in RIPA lysis buffer (Santa Cruz 
Biotechnology, USA). Protein concentration was measured 
by Pierce 660 nm protein assay (Thermo Scientific, 
Rockford, USA) according to the manufacturer’s 
protocol. Protein samples from the treated cell lysates 
were separated by 10% or 6-12% SDS-PAGE, and further 
electrotransferred onto PVDF membranes (Millipore), 
which were then washed and blocked with 1× TBS 
containing 0.1% (v/v) Tween 20 and 5% (w/v) skimmed 
milk for 1 h at room temperature (RT). After washing, the 
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membranes were incubated with the indicated primary 
antibody for at least 12 h, and further incubated with an 
appropriate horseradish peroxidase-conjugated secondary 
antibody at RT for 2 h. Visualization of reactive protein 
bands was performed using enhanced chemiluminescent 
detection reagents (Amersham; Thermo Scientific), and 
the expression level of reactive protein bands was further 
quantified using Image Studio Lite software (LI-COR 
Biosciences).
Immunofluorescence cell staining
MDA-MB-231 cells (2 × 104 cells/well) were plated 
on glass slips in 24-well culture plates and incubated 
overnight to allow cell adhesion, and then treated with 
vehicle (DMSO, 0.5%), DET (11 μM), DETD-35 (3 
μM), or PTX (1 μM) for 24 h. The vehicle and compound 
treated cells were fixed with ice-cold 100% methanol 
for 10 min, and then permeabilized and blocked with 
blocking buffer (1× PBS containing 0.1% (v/v) Tween 20 
and 3% (w/v) BSA) at RT for 1 h. After blocking, cells 
on glass slips were incubated with the indicated primary 
antibody in blocking buffer (1:100) at 4°C for 18 h, and 
then washed and stained with FITC conjugated secondary 
antibody (1:200) at RT for 3 h (Jackson ImmunoResearch 
Laboratories). The nuclei region of treated cells was 
stained with DAPI (Sigma-Aldrich), and the cells were 
further mounted onto a glass slide with Gold Antifade 
Reagent (ProLong). Visualization and capture of stained 
cells was accomplished through the Zeiss LSM 780 plus 
Elyra confocal microscope.
Measurement of reactive oxygen species
To determine reactive oxygen species (ROS) 
level, treated cells were measured using the Total ROS 
Detection Kit according to the manufacturer’s protocol 
(Enzo; Catalog No. 51011). The cells (1 × 105 cells) were 
grown on 10-cm plates overnight and treated with vehicle 
(DMSO, 0.5%), DET (11 μM), DETD-35 (3 μM), or 
PTX (1 μM) for 1 h. Then, the cells were collected and 
resuspended in ROS detection solution (green probe) 
that directly reacts with a wide range of reactive species, 
for example hydroxyl radicals, hydrogen peroxide, 
peroxynitrite, peroxy radical, and nitric oxide, and the cells 
were further stained for 30 min at 37°C. After staining 
cells, the ROS level of treated cells was determined by 
flow cytometry.
Transmission electron microscopy
The cells were prefixed with 0.1 M cacodylate 
buffer containing 2.5% glutaraldehyde and 0.1% tannic 
acid for 30 min at RT, and washed with PBS. Postfixing 
was performed by using 1% osmium tetroxide in 0.1 M 
cacodylate buffer at RT for 30 min, and then washed and 
dehydrated with graded series of ethanol (30-100%). 
After dehydration, the cells were embedded in Spurr’s 
resin (EMS), and polymerized at 70°C for 48 h. The 
polymerized samples were sectioned and stained with 
uranyl acetate and lead citrate, and further examined 
using electron microscopy (FEI Tecnai G2 F20 S-TWIN 
FEGTEM).
Transfection of small hairpin RNA
For knockdown of specific genes in cancer cells, 
the lentiviral-based small hairpin RNA (shRNA) clones 
employed in this study were purchased from the RNAi 
Core Facility, Academia Sinica. The cells (2 × 104 cells/
well) were plated in 12-well culture plates and incubated 
overnight to allow cell adhesion, and then replaced with 
fresh media containing polybrene and virus carrying 
shRNA targeting LC3, RAF1, or control (shLacZ) and 
then incubated overnight again. The LC3 and RAF1 
shRNA sequences are as follows: 5′-CCGGCGCTTA
CAGCTCAATGCTAATCTCGAGATTAGCATTGAG
CTGTAAGCGTTTTTTG-3′ for LC3; 5′-CCGGCATG
AGTATTTAGAGGAAGTACTCGAGTACTTCCTC
TA AATACTCATGTTTTT-3′ for RAF1. Selection of 
efficiently infected cells, the fresh media containing 
puromycin was used to incubate the cells for 48 h at 37°C.
Statistical analysis
All data are presented as means ± standard 
deviation (SD). Statistical analysis of experimental data 
was performed by the SAS program (SAS Institute), and 
significant differences between different treatment groups 
were determined by ANOVA. P values of less than 0.05 
were considered statistically significant.
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